Monoclonal Antibodies Market Analysis, Overview and Forecasts 2016-2020
- Submitted by: Marketreport
- Views: 77
- Category: Other
- Date Submitted: 08/09/2016 03:42 AM
- Pages: 3
- Report this Essay
Technavio Announces the Publication of its Research Report Global Monoclonal Antibodies (mAbs) Market 2016-2020
Technavio recognizes the following companies as the key players in the global monoclonal antibodies (mAbs) market: AbbVie, Amgen, Bristol-Myers Squibb, F. Hoffmann-La Roche, Johnson & Johnson, and Merck.
Other Prominent Vendors in the market are: AbGenomics, ADC Therapeutics, Agensys, Alexion Pharmaceuticals, ALMAC Group, Ambrx, Astellas Pharma, AstraZeneca, Bayer HealthCare, Biogen, Celgene, Celldex Therapeutics, Daiichi Sankyo, Eisai, Eli Lilly, Formation Biologics, Genmab, GlaxoSmithKline, Human Genome Sciences, Immunogen, MedImmune, Novartis, Pfizer, Seattle Genetics, Stemcentrx, Synthon Biopharmaceuticals, Takeda Pharmaceuticals, Teva, and UCB.
Browse full report with TOC@ https://marketreportscenter.com/reports/344104/global-monoclonal-antibodies-market-2016-2020
Commenting on the report, an analyst from Technavios team said: The emergence of biosimilars will be a key trend leading to the market growth. In recent years, the population of the aging has increased due to the availability of advanced medical care. This rising aging population has also increased the prevalence of various chronic diseases, such as rheumatoid arthritis, psoriatic arthritis, cancers and metabolic disorders, leading to a high demand for quality care. Biosimilars will likely play a prominent role in this scenario.
According to the report, one of the key drivers for market growth will be special regulatory drug designations. The US FDA's Office of Orphan Products Development (OOPD) aims to develop and evaluate drugs, biologics, and devices that effectively treat and diagnose rare diseases or conditions, and provides incentives to companies that develop drugs for rare disorders. It also grants orphan status to drugs and biologics proven to be effective and safe in treating rare diseases.
Further, the report states that threat from chemotherapy and off-label...
Technavio recognizes the following companies as the key players in the global monoclonal antibodies (mAbs) market: AbbVie, Amgen, Bristol-Myers Squibb, F. Hoffmann-La Roche, Johnson & Johnson, and Merck.
Other Prominent Vendors in the market are: AbGenomics, ADC Therapeutics, Agensys, Alexion Pharmaceuticals, ALMAC Group, Ambrx, Astellas Pharma, AstraZeneca, Bayer HealthCare, Biogen, Celgene, Celldex Therapeutics, Daiichi Sankyo, Eisai, Eli Lilly, Formation Biologics, Genmab, GlaxoSmithKline, Human Genome Sciences, Immunogen, MedImmune, Novartis, Pfizer, Seattle Genetics, Stemcentrx, Synthon Biopharmaceuticals, Takeda Pharmaceuticals, Teva, and UCB.
Browse full report with TOC@ https://marketreportscenter.com/reports/344104/global-monoclonal-antibodies-market-2016-2020
Commenting on the report, an analyst from Technavios team said: The emergence of biosimilars will be a key trend leading to the market growth. In recent years, the population of the aging has increased due to the availability of advanced medical care. This rising aging population has also increased the prevalence of various chronic diseases, such as rheumatoid arthritis, psoriatic arthritis, cancers and metabolic disorders, leading to a high demand for quality care. Biosimilars will likely play a prominent role in this scenario.
According to the report, one of the key drivers for market growth will be special regulatory drug designations. The US FDA's Office of Orphan Products Development (OOPD) aims to develop and evaluate drugs, biologics, and devices that effectively treat and diagnose rare diseases or conditions, and provides incentives to companies that develop drugs for rare disorders. It also grants orphan status to drugs and biologics proven to be effective and safe in treating rare diseases.
Further, the report states that threat from chemotherapy and off-label...